Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

“The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus,” he added. Afrezza has been evaluated in over 70 ...

“Afrezza is a rapid-acting insulin delivered ... The availability of insulin to be inhaled through the lungs will provide a new and innovative option for patients with diabetes mellitus ...

MUMBAI:Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday. The ...

“The availability of Afrezza has the potential to help so many people in India living with diabetes in improving glycemic control via a non-injectable and convenient delivery of inhaled insulin ...

Mumbai, Dec 11 Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on ...

“Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide, is an exciting milestone for MannKind and our partner Cipla,” said Michael Castagna, PharmD, ...